Article

Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use.

New England Journal of Medicine (Impact Factor: 54.42). 04/1986; 314(11):719-20.
Source: PubMed
0 Bookmarks
 · 
39 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute and chronic toxicity tests were conducted with three aquatic species to determine the effects of metals combined as mixtures at proposed water quality criteria concentrations and at multiples of the LC50 and maximum acceptable toxicant concentration (MATC) obtained from tests on six metals. These studies were the first part of a larger research effort to derive water-quality criteria for combined pollutants by the U.S. Environmental Protection Agency.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gepirone is an azapirone derivative with partial agonist activity at the post-synaptic serotonin (5-hydroxytryptamine) 5-HT1A receptor. In contrast to buspirone, gepirone lacks appreciable in vitro affinity for the dopamine D2 receptor, and exhibits only limited dopaminergic activity in vivo. The drug is active in several animal models considered predictive of antidepressant and anxiolytic activity, and is currently under development as a potential treatment for affective and anxiety disorders. The limited number of controlled clinical trials performed to date indicate that gepirone is of superior therapeutic efficacy to placebo on short term (≤ 10 weeks) administration to outpatients with generalised anxiety disorder (dosage range ≤ 60 mg/day) and major depressive disorder or atypical depression (dosage range ≤ 90 mg/day). The antidepressant effect of gepirone appears to be additional to its anxiolytic effect. As with buspirone, onset of the anxiolytic effect of gepirone appears to be delayed (≈ 2 to 4 weeks) relative to that of the benzodiazepines. The tolerability profile of gepirone mirrors that of buspirone: gepirone is nonsedating, lacks anticholinergic effects, and appears to be of low abuse potential. Gepirone has a possible role in the treatment of major depression, particularly that of the milder, non-endogenous or non-melancholic subtype, major depression associated with generalised anxiety, atypical depression, and chronic generalised anxiety disorder.
    CNS Drugs 05/1994; 1(5). · 4.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anxiety occupies a central place in the psychopathology of demented or not elderly persons. In this population, its treatment is generally considered as difficult, especially due to adverse effects of psychotropic drugs, and particularly benzodiazepines. In fact, the treatment of anxiety should not be restricted in benzodiazepines and pharmacotherapy. It is well-codified in a global approach of the aged persons, based on the recognition of their individual specificities, the potential role played by their environment and a perfect awareness of the pharmacological properties of psychotropic drugs.
    NPG Neurologie - Psychiatrie - Gériatrie 12/2005; 5(30).